The Motley Fool··Eric TrieORBIMED Advisors Reduces Terns Pharma Position Despite 858% Annual Gain
ORBIMED Advisors divested 5.4 million Terns Pharma shares worth $125 million despite the stock's 858% annual gain, reducing its stake as the biotech company advances clinical programs.
LLYTERNEWvaluationbiotech